177Lu-IM-3050

July 20, 2026: Immunome, Inc. (NASDAQ: IMNM) announced the first patient was dosed in its Phase 1 first-in-human trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand therapy delivering lutetium-177, in participants with FAP-expressing advanced solid tumors. The open-label, multicenter study includes dose escalation and expansion to evaluate safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity. Dose escalation will test repeated escalating doses to determine the maximum tolerated dose and/or recommended expansion dose, followed by expansion to further assess safety/tolerability at the candidate recommended dose.

The release also notes Immunome’s pipeline includes varegacestat (gamma secretase inhibitor; NDA submitted to the U.S. FDA), IM-1021 (clinical-stage ROR1 ADC), and IM-1617 (clinical-stage solid tumor ADC).